Adiposs has developed ImageBAT, a first-in-class medical imaging product for brown adipose tissue.
ImageBAT-enhanced CT scan is fast, pain-free and will be available in every hospital worldwide.
ImageBAT enables early detection of body wasting before irreversible weight loss.
January 10, 2022
Adiposs raises CHF 1.8M Pre-Series A Funding led by Privilège Ventures to start Clinical Trials and Product Industrialization
Adiposs 2021 | All rights reserved
Andrej is the Chief Executive Officer and co-founder of Adiposs. He holds a master’s degree in pharmaceutical sciences and a PhD in pharmaceutical chemistry. Andrej is the co-inventor of ImageBAT. He was a senior lecturer in pharmaceutics at the University of Geneva, where he developed molecules for diagnosis of diabetes, obesity and cancer. Andrej has co-authored more than 30 scientific papers and holds several patents in the fields of medical imaging, photodynamic therapy and nanotechnology. He has worked in the field of diagnostic medical imaging for over 10 years leading multidisciplinary teams and projects in academia and start-up companies.
Justyna is the Chief Operating Officer and co-founder of Adiposs. She has a double master’s degree in Business Administration & Management and in International Economic Relations and over 10 years of extensive business, finance and competitive intelligence experience. She has spent a big part of her professional life working at KPMG where she provided audit, consulting, advisory and due diligence services to a wide range of public and private companies in multiple jurisdictions.
Nathalie is the Chief Technical Officer of Adiposs. She holds a master’s degree in pharmacy and a PhD in pharmaceutical technology from the University of Geneva. She is responsible for preclinical development of ImageBAT and GMP production. Nathalie has 10 years of experience in the development of advanced nanotechnology pharmaceutical systems and medical imaging agents in academia and start-up companies. She also has experience in designing clinical trials and is coordinating activities of the clinical pipeline of Adiposs.
Duc brings to Adiposs over twenty years of experience in drug discovery and drug development from big pharma companies (Sanofi-Aventis, Pfizer, Lundbeck) and biotech start-ups (Preglem, Arisgen, EspeRare, Prexton Therapeutics). Duc’s experience extends across multiple therapeutic areas including cardiovascular, anti-infective, urology, epigenetics, CNS, rare disease and reproductive medicine. He has successfully delivered a number of projects into clinical development, up to registration. At Adiposs, Duc is responsible for providing IND-enabling Preclinical, Early Clinical, and Chemistry, Manufacturing and Control (CMC) leadership to support regulatory submissions.
Bams is a UK-registered physician and clinical scientist with specializations in clinical pharmacology and pharmaceutical medicine. He has over 15 years of experience in clinical medicine and medical research and over 30 years of experience in global drug development leadership roles in Aventis, Pfizer, Astellas, AstraZeneca and GSK. Bams was involved in the translational science activities and clinical development of small molecule drugs in multiple therapy areas, including urology, oncology, cardiovascular and neurology. After that, his focus has been the development of biologics and advanced therapy medicinal products (ATMPs) in several therapy areas including oncology, immuno-inflammation, neurology, respiratory disorders and diabetes.
